- Home
- HOOK vs COHN Comparison
HOOK vs COHN Comparison
Compare HOOK & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- COHN
- Stock Information
- Founded
- HOOK 2011
- COHN 1999
- Country
- HOOK United States
- COHN United States
- Employees
- HOOK N/A
- COHN N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- COHN Investment Bankers/Brokers/Service
- Sector
- HOOK Health Care
- COHN Finance
- Exchange
- HOOK Nasdaq
- COHN Nasdaq
- Market Cap
- HOOK 9.3M
- COHN 17.8M
- IPO Year
- HOOK 2019
- COHN N/A
- Fundamental
- Price
- HOOK $1.47
- COHN $8.80
- Analyst Decision
- HOOK Buy
- COHN
- Analyst Count
- HOOK 4
- COHN 0
- Target Price
- HOOK $10.67
- COHN N/A
- AVG Volume (30 Days)
- HOOK 134.3K
- COHN 5.4K
- Earning Date
- HOOK 05-20-2025
- COHN 05-01-2025
- Dividend Yield
- HOOK N/A
- COHN 11.36%
- EPS Growth
- HOOK N/A
- COHN N/A
- EPS
- HOOK N/A
- COHN N/A
- Revenue
- HOOK $43,946,000.00
- COHN $84,171,000.00
- Revenue This Year
- HOOK N/A
- COHN N/A
- Revenue Next Year
- HOOK N/A
- COHN N/A
- P/E Ratio
- HOOK N/A
- COHN N/A
- Revenue Growth
- HOOK 118.32
- COHN N/A
- 52 Week Low
- HOOK $0.72
- COHN $6.10
- 52 Week High
- HOOK $10.50
- COHN $12.82
- Technical
- Relative Strength Index (RSI)
- HOOK 67.61
- COHN 61.74
- Support Level
- HOOK $1.14
- COHN $8.34
- Resistance Level
- HOOK $1.67
- COHN $9.05
- Average True Range (ATR)
- HOOK 0.16
- COHN 0.39
- MACD
- HOOK 0.10
- COHN 0.16
- Stochastic Oscillator
- HOOK 78.69
- COHN 86.63
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About COHN Cohen & Company Inc.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.